Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tazarotene
Drug ID BADD_D02120
Description Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
Indications and Usage Used to treat psoriasis, acne and sun damaged skin (photodamage).
Marketing Status approved; investigational
ATC Code D05AX05
DrugBank ID DB00799
KEGG ID D01132
MeSH ID C086827
PubChem ID 5381
TTD Drug ID D0BM5G
NDC Product Code 51672-1374; 68308-745; 16110-915; 51014-7755; 45802-442; 0023-0042; 60758-556; 68308-685; 17337-0064; 0713-0804; 17337-0065; 51552-1519; 71052-558; 16110-916; 0023-8335; 0713-0670; 48943-0028; 16110-833; 0187-2098; 51672-1373; 66039-836; 45802-436; 60758-561; 55679-114; 73309-058; 51862-295; 0713-0805; 16110-042; 48943-0027
UNII 81BDR9Y8PS
Synonyms tazarotene | ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate | Tazorac | AGN 190168 | AGN-190168
Chemical Information
Molecular Formula C21H21NO2S
CAS Registry Number 118292-40-3
SMILES CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.0010.003966%-
Application site dermatitis08.02.01.018; 12.07.01.018; 23.03.04.0140.003966%-
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.0050.010965%-
Application site irritation08.02.01.003; 12.07.01.0030.002644%-
Application site pain08.02.01.004; 12.07.01.0040.009643%-
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.0040.002644%-
Application site rash08.02.01.016; 12.07.01.016; 23.03.13.008---
Blister12.01.06.002; 23.03.01.001---
Blood triglycerides increased13.12.03.001---
Burning sensation08.01.09.029; 17.02.06.0010.006610%-
Cheilitis07.05.01.001; 23.03.03.025--
Condition aggravated08.01.03.0040.002644%-
Dermatitis23.03.04.002---
Dermatitis bullous23.03.01.002--
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.0040.000778%-
Discomfort08.01.08.003---
Drug hypersensitivity10.01.01.0010.002644%-
Drug ineffective08.06.01.0060.010576%-
Dry skin23.03.03.0010.002644%
Eczema23.03.04.006--
Erythema23.03.06.0010.013220%-
Facial pain08.01.08.012--
Haemoglobin13.01.05.018---
Hypersensitivity10.01.03.0030.002644%
Hypertriglyceridaemia14.08.02.001--
Impetigo11.01.12.006; 23.11.02.011---
Instillation site pain08.02.01.008; 12.07.01.008---
Leukoderma23.05.02.001---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
The 1th Page    1 2    Next   Last    Total 2 Pages